A targeted salvage therapy with brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients who received autologuos stem cell transplantation (ASCT).

Nurdan Taçyıldız(Ankara University), Esra Pekpak(Ankara University), Emel Ünal(Ankara University), Gülşah Tanyıldız(Ankara University), Handan Dinçaslan(Pediatric Oncology Group), Gülsan Yavuz
Journal of Clinical Oncology
May 20, 2015
Cited by 1


Related Papers